Results 171 to 180 of about 354,322 (345)

Navigating the evolving management of smoldering multiple myeloma. [PDF]

Hemasphere
Hammami MB, Canevarolo RR, Silva AS, Alsina M, Kumar N, Baz R, Shain KH.   +6 more
europepmc   +1 more source

Health‐related quality of life and disease‐specific complaints among multiple myeloma patients up to 10 yr after diagnosis: results from a population‐based study using the PROFILES registry

, 2012
Floortje Mols, Simone Oerlemans, Allert H. Vos, Ad Koster, S. Verelst, Pieter Sonneveld, Lonneke V. van de Poll‐Franse   +6 more
openalex   +2 more sources

Multiple Myeloma [PDF]

CA: A Cancer Journal for Clinicians, 1966
L F, Craver, D G, Miller
openaire   +2 more sources

Fat Mass and Obesity‐Associated Protein Contributes to Tumorigenesis and Drug Resistance of Diffuse Large B‐Cell Lymphoma by Suppressing N6‐Methyladenosine Methylation of Myc

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Ibrutinib resistance remains a major obstacle in the treatment of diffuse large B‐cell lymphoma (DLBCL). Fat mass and obesity‐associated protein (FTO) has been implicated in drug resistance through its regulation of N6‐methyladenosine (m6A) modifications; however, whether FTO mediates ibrutinib resistance in DLBCL remains unclear.
Ting‐Ting Lu, Jin‐Hao Chen, Yan‐Fang Wang, Xiao Wu, Hui‐Yun Ni, Qiu‐Rong Zhang   +5 more
wiley   +1 more source

Daratumumab- ²²⁵ Actinium conjugate demonstrates greatly enhanced antitumor activity against experimental multiple myeloma tumors [PDF]

, 2019
Wojciech Dawicki, Kevin J. Allen, Rubin Jiao, Mackenzie E. Malo, Muath Helal, Mark S. Berger, Dale L. Ludwig, Ekaterina Dadachova   +7 more
openalex   +1 more source

Data‐Independent Acquisition Mass Spectrometry in Tumor Classification and Cancer Biomarker Research

Mass Spectrometry Reviews, EarlyView.
Abstract Cancer treatment is far from optimal also because current classification systems do not reflect the complex molecular status of the tumor and its phenotype in sufficient detail. To construct molecular tumor classifiers, omics tools provide complex molecular data reflecting many aspects from genotype to phenotype.
Jan Simonik, Petr Lapcik, Pavla Bouchalova, Pavel Bouchal   +3 more
wiley   +1 more source

Elranatamab Exposure-Safety Analysis in Relapsed or Refractory Multiple Myeloma. [PDF]

J Clin Pharmacol
Soltantabar P, Hibma J, Wang D, Conte U, Hickman A, Elmeliegy M.   +5 more
europepmc   +1 more source

Positive transcription elongation factor b (P-TEFb) is a therapeutic target in human multiple myeloma

, 2017
Yu Zhang, Liang Zhou, Yun Leng, Yun Dai, Robert Z. Orlowski, Steven Grant   +5 more
openalex   +2 more sources

Targeting MK2 Is a Novel Approach to Interfere in Multiple Myeloma [PDF]

, 2019
Mengjie Guo, Dongdong Sun, Zhimin Fan, Yuxia Yuan, Miaomiao Shao, Jianhao Hou, Yuqi Zhu, Rongfang Wei, Yan Zhu, Jinjun Qian, Fei Li, Ye Yang, Chunyan Gu   +12 more
openalex   +1 more source

The SCARLET Trial: Radiotheranostics in Multiple Myeloma. [PDF]

Radiol Imaging Cancer
Jain S, Graham MM.
europepmc   +1 more source